<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05627921</url>
  </required_header>
  <id_info>
    <org_study_id>09.2022.1312</org_study_id>
    <nct_id>NCT05627921</nct_id>
  </id_info>
  <brief_title>The Effect of Botulinum Toxin and ESWT Applications on Spasticity and Functionality in Cerebral Palsy Patients</brief_title>
  <official_title>The Effect of Botulinum Toxin and ESWT Applications on Spasticity and Functionality in Cerebral Palsy Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marmara University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Marmara University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cerebral Palsy (CP) is a group of movement and posture disorders associated with a&#xD;
      non-progressive affect during brain development that can cause limitation of activity and&#xD;
      disability. The most common movement disorders in CP are spasticity and dystonia. Currently,&#xD;
      the treatment of muscle stiffness called spasticity includes physiotherapy, casting and&#xD;
      device, various drugs and surgical treatment. Botulinum toxin injection into the muscle also&#xD;
      acts by reducing muscle contraction. ESWT is a method used in various musculoskeletal&#xD;
      diseases. It has been previously applied to pediatric patients and has been shown to be&#xD;
      effective and painless in ankle muscle stiffness. However, there are few studies&#xD;
      investigating the effect of ESWT on functionality.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cerebral palsy (CP) is a permanent, non-progressive disorder in movement, posture, and motor&#xD;
      development that occurs in the immature fetal or neonatal brain. Motor disturbances may be&#xD;
      accompanied by secondary musculoskeletal problems such as spasticity and contractures. In the&#xD;
      treatment of spasticity, various treatments such as exercise, occupational therapies,&#xD;
      ultrasound, electrical stimulation, physiotherapy applications such as ESWT, orthoses, oral&#xD;
      antispasticity agents, botulinum toxin injection, intrathecal baclofen, and surgery are&#xD;
      applied. Botulinum toxin type A is one of the most widely used pharmacological treatments in&#xD;
      the treatment of focal spasticity. Repeated injections may lead to the formation of&#xD;
      neutralizing antibodies, resulting in a decrease in BoNT-A activity. In addition, a decrease&#xD;
      in Botulinum toxin response may be observed due to the increase in intramuscular fat and&#xD;
      connective tissue. In addition, in some patients with diffuse spasticity, the total dose of&#xD;
      BoNT-A required may exceed the maximum dose. Therefore, various non-pharmacological treatment&#xD;
      methods are recommended in addition to BoNT-A in the management of spasticity. Extracorporeal&#xD;
      shock wave therapy (ESWT) is a treatment method for applying high pressure waves to the body.&#xD;
      The effectiveness of ESWT on spasticity in patients with upper motor neuron damage has been&#xD;
      demonstrated in previous studies. However, there are few studies investigating the effect of&#xD;
      ESWT after BoNT-A injection on muscle tone, functionality and quality of life. Previous&#xD;
      studies have shared the results of short-term follow-up after ESWT and BoNT-A injection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2022</start_date>
  <completion_date type="Anticipated">July 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomized into two equal groups using the closed envelope system. The patients in the first group will be injected with Botulinum Toxin-A with the Stumplex device into the spastic muscle.&#xD;
The patients in the second group will be injected with Botulinum toxin with the same procedure. 1 week after the injection, patients will receive 3 sessions of radial ESWT treatment, 1 session/week. rESWT application will be applied with the 'MODUS ESWT' device and a 35 mm radial soft applicator will be used.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
    <masking_description>The person performing the examinations and evaluating the data was blind to the treatment administered.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Modified Tardieu Scale</measure>
    <time_frame>T0:Patients will be evaluated before botulinum toxin injection.</time_frame>
    <description>The intensity of muscle tone is evaluated at different determined rates. At the joint, the first angle at which the increase in resistance is detected is recorded. The range of motion is compared to the angle at completion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Modified Tardieu Scale</measure>
    <time_frame>T1:Patients will be evaluated 1 week after botulinum toxin injection.</time_frame>
    <description>The intensity of muscle tone is evaluated at different determined rates. At the joint, the first angle at which the increase in resistance is detected is recorded. The range of motion is compared to the angle at completion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Modified Tardieu Scale</measure>
    <time_frame>T2:Patients will be evaluated 1 month after botulinum toxin injection.</time_frame>
    <description>The intensity of muscle tone is evaluated at different determined rates. At the joint, the first angle at which the increase in resistance is detected is recorded. The range of motion is compared to the angle at completion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Modified Tardieu Scale</measure>
    <time_frame>T3:Patients will be evaluated 3 months after botulinum toxin injection.</time_frame>
    <description>The intensity of muscle tone is evaluated at different determined rates. At the joint, the first angle at which the increase in resistance is detected is recorded. The range of motion is compared to the angle at completion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Modified Tardieu Scale</measure>
    <time_frame>T4:Patients will be evaluated 6 months after botulinum toxin injection.</time_frame>
    <description>The intensity of muscle tone is evaluated at different determined rates. At the joint, the first angle at which the increase in resistance is detected is recorded. The range of motion is compared to the angle at completion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modified Ashworth Scale</measure>
    <time_frame>T0:Patients will be evaluated before botulinum toxin injection.</time_frame>
    <description>muscle tone 0 (0) - No increase in muscle tone 1 (1) - Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension&#xD;
1+ (2) - Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the ROM 2 (3) - More marked increase in muscle tone through most of the ROM, but affect part(s) easily moved 3 (4) - Considerable increase in muscle tone passive, movement difficult 4 (5) - Affected part(s) rigid in flexion or extension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Ashworth Scale</measure>
    <time_frame>T1:Patients will be evaluated 1 week after botulinum toxin injection.</time_frame>
    <description>muscle tone 0 (0) - No increase in muscle tone 1 (1) - Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension&#xD;
1+ (2) - Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the ROM 2 (3) - More marked increase in muscle tone through most of the ROM, but affect part(s) easily moved 3 (4) - Considerable increase in muscle tone passive, movement difficult 4 (5) - Affected part(s) rigid in flexion or extension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Ashworth Scale</measure>
    <time_frame>T2:Patients will be evaluated 1 month after botulinum toxin injection.</time_frame>
    <description>muscle tone 0 (0) - No increase in muscle tone 1 (1) - Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension&#xD;
1+ (2) - Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the ROM 2 (3) - More marked increase in muscle tone through most of the ROM, but affect part(s) easily moved 3 (4) - Considerable increase in muscle tone passive, movement difficult 4 (5) - Affected part(s) rigid in flexion or extension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Ashworth Scale</measure>
    <time_frame>T3:Patients will be evaluated 3 months after botulinum toxin injection.</time_frame>
    <description>muscle tone 0 (0) - No increase in muscle tone 1 (1) - Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension&#xD;
1+ (2) - Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the ROM 2 (3) - More marked increase in muscle tone through most of the ROM, but affect part(s) easily moved 3 (4) - Considerable increase in muscle tone passive, movement difficult 4 (5) - Affected part(s) rigid in flexion or extension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Ashworth Scale</measure>
    <time_frame>T4:Patients will be evaluated 6 months after botulinum toxin injection.</time_frame>
    <description>muscle tone 0 (0) - No increase in muscle tone 1 (1) - Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension&#xD;
1+ (2) - Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the ROM 2 (3) - More marked increase in muscle tone through most of the ROM, but affect part(s) easily moved 3 (4) - Considerable increase in muscle tone passive, movement difficult 4 (5) - Affected part(s) rigid in flexion or extension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Range of Motion</measure>
    <time_frame>T0:Patients will be evaluated before botulinum toxin injection.</time_frame>
    <description>The joint is positioned according to the anatomical position and this position is considered as 0 starting position. Active and passive joint movement is measured with the help of a goniometer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Range of Motion</measure>
    <time_frame>T1:Patients will be evaluated 1 week after botulinum toxin injection.</time_frame>
    <description>The joint is positioned according to the anatomical position and this position is considered as 0 starting position. Active and passive joint movement is measured with the help of a goniometer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Range of Motion</measure>
    <time_frame>T2:Patients will be evaluated 1 month after botulinum toxin injection.</time_frame>
    <description>The joint is positioned according to the anatomical position and this position is considered as 0 starting position. Active and passive joint movement is measured with the help of a goniometer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Range of Motion</measure>
    <time_frame>T3:Patients will be evaluated 3 months after botulinum toxin injection.</time_frame>
    <description>The joint is positioned according to the anatomical position and this position is considered as 0 starting position. Active and passive joint movement is measured with the help of a goniometer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Range of Motion</measure>
    <time_frame>T4:Patients will be evaluated 6 months after botulinum toxin injection.</time_frame>
    <description>The joint is positioned according to the anatomical position and this position is considered as 0 starting position. Active and passive joint movement is measured with the help of a goniometer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BIDA( Bodily Functioning Assessment Tool)</measure>
    <time_frame>T0:Patients will be evaluated before botulinum toxin injection.</time_frame>
    <description>The BIDA has been created to evaluate functional status, to assess therapeutic needs and changes after treatment in 2 to 18 years old children and adolescents who have orthopedic problems. The BIDAhas three forms; parent form for children, parent and self report forms for adolescents. Instrument has 86 items assessing 'upper extremity and physical function', 'transfer and basic mobility', 'sports and physical function', 'pain/comfort', 'happiness', 'global functioning' and 'expectations from treatment domains'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BIDA( Bodily Functioning Assessment Tool)</measure>
    <time_frame>T1:Patients will be evaluated 1 month after botulinum toxin injection.</time_frame>
    <description>The BIDA has been created to evaluate functional status, to assess therapeutic needs and changes after treatment in 2 to 18 years old children and adolescents who have orthopedic problems. The BIDAhas three forms; parent form for children, parent and self report forms for adolescents. Instrument has 86 items assessing 'upper extremity and physical function', 'transfer and basic mobility', 'sports and physical function', 'pain/comfort', 'happiness', 'global functioning' and 'expectations from treatment domains'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BIDA( Bodily Functioning Assessment Tool)</measure>
    <time_frame>T2:Patients will be evaluated 3 months after botulinum toxin injection.</time_frame>
    <description>The BIDA has been created to evaluate functional status, to assess therapeutic needs and changes after treatment in 2 to 18 years old children and adolescents who have orthopedic problems. The BIDAhas three forms; parent form for children, parent and self report forms for adolescents. Instrument has 86 items assessing 'upper extremity and physical function', 'transfer and basic mobility', 'sports and physical function', 'pain/comfort', 'happiness', 'global functioning' and 'expectations from treatment domains'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BIDA( Bodily Functioning Assessment Tool)</measure>
    <time_frame>T3:Patients will be evaluated 6 months after botulinum toxin injection.</time_frame>
    <description>The BIDA has been created to evaluate functional status, to assess therapeutic needs and changes after treatment in 2 to 18 years old children and adolescents who have orthopedic problems. The BIDAhas three forms; parent form for children, parent and self report forms for adolescents. Instrument has 86 items assessing 'upper extremity and physical function', 'transfer and basic mobility', 'sports and physical function', 'pain/comfort', 'happiness', 'global functioning' and 'expectations from treatment domains'.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cerebral Palsy, Spastic</condition>
  <arm_group>
    <arm_group_label>botulinum toxin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>botilinum toxin and ESWT group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Extracorporeal Shock Wave Therapy</intervention_name>
    <description>Spastic muscles will be determined by examination. Botulinum toxin-A will be injected into the spastic muscles with Stumplex. 1 week after the injection, patients will receive 3 sessions of radial ESWT treatment, 1 session/week. rESWT application will be applied with the 'MODUS ESWT' device and a 35 mm radial soft applicator will be used. rESWT will be applied with a soft applicator. The soft applicator is designed for application to sensitive and painful areas and applications will be painless.Shock waves will be applied at 1500/beat, 8 Hz, 0.030 Mj/mm2, 2 bar per muscle.</description>
    <arm_group_label>botilinum toxin and ESWT group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botilinum Toxin injection</intervention_name>
    <description>Spastic muscles will be determined by examination. Botulinum toxin-A will be injected into the spastic muscles with Stumplex.</description>
    <arm_group_label>botilinum toxin and ESWT group</arm_group_label>
    <arm_group_label>botulinum toxin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Having a diagnosis of Spastic Cerebral Palsy confirmed by a pediatric neurologist,&#xD;
             Patients with a spasticity value of at least 2 in the evaluation with the Modified&#xD;
             Ashworth Scale (MAS), Patients with Botulinum Toxin injection indication by their&#xD;
             physician, Having a mental level to understand the commands of the person making the&#xD;
             assessment, agree to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed with dyskinetic, ataxic, mixed type cerebral palsy,&#xD;
             Hypersensitivity to Onabotulinumtoxin A or any of the excipients, Infection at the&#xD;
             planned injection site or sites, Having an uncontrolled epileptic seizure, Upper/lower&#xD;
             extremity contracture, coagulopathy, Refusing to participate in the study, The patient&#xD;
             is not oriented and cooperative, Contraindication of anesthesia for the group&#xD;
             requiring anesthesia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nurahsen Zaben, Dr</last_name>
    <phone>05453492877</phone>
    <email>nrhsn_dmr@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Evrim Karadag SaygÄ±, Prof</last_name>
    <email>evrimkaradag4@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Marmara University School of Medicine Department of Physical Medicine and Rehabilitation</name>
      <address>
        <city>Istanbul</city>
        <zip>34899</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nurahsen Zaben, Dr.</last_name>
      <phone>05453492877</phone>
      <email>nrhsn_dmr@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 16, 2022</study_first_submitted>
  <study_first_submitted_qc>November 16, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 28, 2022</study_first_posted>
  <last_update_submitted>November 16, 2022</last_update_submitted>
  <last_update_submitted_qc>November 16, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 28, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>botilinum toxin</keyword>
  <keyword>spasticity</keyword>
  <keyword>eswt</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscle Spasticity</mesh_term>
    <mesh_term>Cerebral Palsy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

